Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial

Barry A Schechter, Maitee Urbieta, Jason Bacharach, Melissa Toyos, Robert Smyth-Medina, Brittany Mitchell, Jodi I Luchs

Open source

DOI
10.2147/opth.s392315
Published
2022-12
Container
Clinical Ophthalmology
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.2147/opth.s392315,
  title = {Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial},
  author = {Barry A Schechter and Maitee Urbieta and Jason Bacharach and Melissa Toyos and Robert Smyth-Medina and Brittany Mitchell and Jodi I Luchs},
  year = {2022},
  journal = {Clinical Ophthalmology},
  doi = {10.2147/opth.s392315},
  url = {https://doi.org/10.2147/opth.s392315}
}

RIS

TY  - JOUR
TI  - Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial
AU  - Barry A Schechter
AU  - Maitee Urbieta
AU  - Jason Bacharach
AU  - Melissa Toyos
AU  - Robert Smyth-Medina
AU  - Brittany Mitchell
AU  - Jodi I Luchs
PY  - 2022
JO  - Clinical Ophthalmology
DO  - 10.2147/opth.s392315
UR  - https://doi.org/10.2147/opth.s392315
ER  - 

APA

Schechter, B. A., Urbieta, M., Bacharach, J., Toyos, M., Smyth-Medina, R., Mitchell, B., & Luchs, J. I. (2022). Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial. Clinical Ophthalmology. https://doi.org/10.2147/opth.s392315

Source records